In October 2021, Xijian Technology was officially established, with technology originating from Prof. Cao Yanping's research group at the Institute of Biomechanics and Medical Engineering, Tsinghua University.

Completed angel round financing in November 2021.

Completed Pre-A round financing in 2022.

• Xijian Technology has officially reached a cooperation agreement with the National Clinical Research Center for Orthopedics and Sports Rehabilitation.
• Xijian Technology has completed the research and development of its original musculoskeletal biomechanics quantification device.
• Beijing Xijian Technology Co., Ltd. has been recognized as an EY-Fudan Most Promising Enterprise of 2023.
• Beijing Xijian Technology Co., Ltd. has been recognized as a "National High-Tech Enterprise"

Completed Pre-A+ round financing in December 2023.

2024.06.15

• The first second-class medical device production system has been put into operation

2024.09.30

• The first global exclusive registration certificate has been approved;
• The construction of marketing channels for rehabilitation, sports, and orthopedic hospital systems has been launched

At the end of 2024

• Recognized among Cyzone's Top 50 Deep-Tech Innovators of 2024
• Selected as one of the first companies on the Tiankai Sci-Tech Innovation Board

From 2025 to the present

• Formally complete Series A financing in June 2025
• Expanded into the out-of-hospital consumer healthcare market, covering TCM, veterinary medicine, medical aesthetics, sports, etc.
• Built a pipeline of medical-grade products covering neurology, orthopedics, plastic surgery, and TCM
• Launched B2C products for at-home chronic disease management